Rungapiromnan W, Mason KJ, Lunt M, et al. - In a large prospective cohort, researchers compared the risk of major cardiovascular events (CVEs; acute coronary syndrome, unstable angina, myocardial infarction and stroke) in individuals with chronic plaque psoriasis treated with adalimumab, etanercept or ustekinumab. Using the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), prospective cohort study investigating the comparative risk of major CVEs was conducted. In the main analysis, 5,468 biologic-naïve patients subsequently exposed (951 ustekinumab; 1,313 etanercept; and 3,204 adalimumab) were included. In addition, the secondary analyses included 2,189 patients receiving methotrexate. Findings revealed that there were no significant differences in the risk of major CVEs between three different biologic therapies and methotrexate. In order to investigate the potential effects of biologic therapies on the occurrence of major CVEs, additional studies with longer-term follow-up are required.